This clinical trial is focused on studying the effects of a medication called Nucala on individuals with severe asthma. Severe asthma is a type of asthma that is difficult to control and often requires more intensive treatment. The medication being tested, Nucala, contains an active substance known as mepolizumab, which is administered as a solution for injection. Mepolizumab is a type of protein that helps reduce inflammation in the airways, potentially improving asthma symptoms.

The purpose of this study is to evaluate how well Nucala can help patients with severe asthma achieve what is known as clinical remission, which means a significant reduction or absence of asthma symptoms. Participants in the study will receive Nucala through subcutaneous injections, which means the medication is injected under the skin. The study will follow participants over a period of 24 months to observe the effects of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

Throughout the study, researchers will monitor the participants’ asthma symptoms and overall health to determine the effectiveness of Nucala in achieving clinical remission. The study aims to provide valuable insights into the potential benefits of Nucala for individuals with severe asthma, helping to improve treatment options for this challenging condition. Participants will be closely observed to ensure their safety and well-being during the trial period.